gemcitabine has been researched along with dactolisib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE; Yen, PL | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
3 other study(ies) available for gemcitabine and dactolisib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Inhibitors; Female; Fibroblasts; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinolines; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2012 |
Preclinical research in treatment of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Imidazoles; Mice; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |